In this study, FLT3 status appeared to be the main biomarker of response to HSP90-inhibitor PU-H71 and MCL1 inhibitor S63845 with elevated susceptibility of FLT3-mutated primary AML samples and the FLT3-ITD-positive cell line MOLM-13. This evidence concerns the gene FLT3 and acute myeloid leukemia.